Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - water for injections, quantity: 5 ml - injection, solution - excipient ingredients: - water for injections bp is used to dissolve or dilute substances or preparations for parenteral administration. ,water for injections bp may also be used as an irrigating solution for small wounds or during minor surgical procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - water for injections, quantity: 20 ml - injection, solution - excipient ingredients: - water for injections bp is used to dissolve or dilute substances or preparations for parenteral administration. ,water for injections bp may also be used as an irrigating solution for small wounds or during minor surgical procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - water for injections, quantity: 10 ml - injection, solution - excipient ingredients: - water for injections bp is used to dissolve or dilute substances or preparations for parenteral administration. ,water for injections bp may also be used as an irrigating solution for small wounds or during minor surgical procedures.

Canada - English - Health Canada

takeda canada inc - immunoglobulin (human) - solution - 10% - immunoglobulin (human) 10% - serums

Canada - English - Health Canada

instituto grifols s.a. - immunoglobulin (human) - solution - 50mg - immunoglobulin (human) 50mg - serums

Canada - English - Health Canada

instituto grifols s.a. - immunoglobulin (human) - solution - 100mg - immunoglobulin (human) 100mg - serums

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - normal immunoglobulin 100 mg/ml - solution for infusion - 100 g/l - active: normal immunoglobulin 100 mg/ml excipient: sorbitol water for injection - replacement therapy indications: - primary immunodeficiency (pi) diseases - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulation indications: - idiopathic thrombocytopaenic purpura (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count. - guillan barre syndrome. - kawasaki disease.

Ireland - English - HPRA (Health Products Regulatory Authority)

bio products laboratory limited - human normal immunoglobulin - solution for infusion - 100 milligram(s)/millilitre - immunoglobulins, normal human; immunoglobulins, normal human, for intravascular adm.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 60 mg/ml - injection, solution - excipient ingredients: maltose; water for injections; human immunoglobulin a - intragam p is indicated in replacement immunoglobulin g (igg) therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; congenital acquired immune deficiency syndrome with recurrent infections. indications as at 21 july 2000: replacement igg therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; congenital acquired immune deficiency syndrome with recurrent infections. immunomodulatory therapy in: idiopathic thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct platelet count; allogenic bone marrow transplantation; kawasaki disease. indications as at 25 february 2003: for replacement immunoglobulin g (igg) therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections, and; congenital acquired immune deficiency syndrome with recurrent infections. for immunomodulatory therapy in: idiopathic thrombocytopenic purpura (itp) in adults or children at high risk of bleeding or prior to surgery to correct platelet count; allogeneic bone marrow transplantation; kawasaki disease, and; guillain-barre syndrome (gbs).

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 60 mg/ml - injection, solution - excipient ingredients: water for injections; human immunoglobulin a; maltose - intragam p is indicated in replacement immunoglobulin g (igg) therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; congenital acquired immune deficiency syndrome with recurrent infections. indications as at 21 july 2000: replacement igg therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; congenital acquired immune deficiency syndrome with recurrent infections. immunomodulatory therapy in: idiopathic thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct platelet count; allogenic bone marrow transplantation; kawasaki disease. indications as at 25 february 2003: for replacement immunoglobulin g (igg) therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections, and; congenital acquired immune deficiency syndrome with recurrent infections. for immunomodulatory therapy in: idiopathic thrombocytopenic purpura (itp) in adults or children at high risk of bleeding or prior to surgery to correct platelet count; allogeneic bone marrow transplantation; kawasaki disease, and; guillain-barre syndrome (gbs).